Cargando…
Combining Intra-Tumoral Treg Depletion with Androgen Deprivation Therapy (ADT): Pre-Clinical Activity in the Myc-CaP Model
INTRODUCTION: Immune checkpoint blockade has shown promising anti-tumor activity against a variety of tumor types. However, responses in castration-resistant prostate cancer remain relatively rare - potentially due to low baseline levels of infiltration. Using an immunocompetent cMyc-driven model (M...
Autores principales: | Shen, Ying-Chun, Ghasemzadeh, Ali, Kochel, Christina M., Nirschl, Thomas R., Francica, Brian J., Lopez-Bujanda, Zoila A., Carrera Haro, Maria A., Tam, Ada, Anders, Robert A., Selby, Mark J., Korman, Alan J., Drake, Charles G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5897134/ https://www.ncbi.nlm.nih.gov/pubmed/29203894 http://dx.doi.org/10.1038/s41391-017-0013-x |
Ejemplares similares
-
Transport of ADT
por: Juha Sakkinen
Publicado: (2006) -
ADT and OBSBOX in 2016
por: Valuch, D, et al.
Publicado: (2017) -
ADT fast losses MD
por: Priebe, A, et al.
Publicado: (2013) -
Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
por: Uemura, Hiroji, et al.
Publicado: (2021) -
ADT and RF after LS1
por: Butterworth, A, et al.
Publicado: (2015)